Skip to content
Home/Companies/Biotech/Cloverleaf Bio

Cloverleaf Bio

Biotech·United States·Active·New
Entry
2026
Hold
New
Status
Active

Who owns Cloverleaf Bio?

Cloverleaf Bio is an American Biotech company, currently owned by 4Bio Partners since 2026.

Hand-verified · updated 2026-09-30

Open JSON · CC-BY
4Bio Partners
Investor
4Bio Partners
4BIO Ventures III · 2022 · Life Sciences VC

Key facts

HQUnited States
SectorBiotech
StatusActive

More from 4BIO Ventures III

Other portfolio companies in the same fund.

Aptadir Therapeutics
Active
BiotechItaly· 2026
Cytospire Therapeutics
Cytospire Therapeutics
Active
BiotechUK· 2026
Actithera
Actithera
Active
BiotechSwitzerland· 2025
Hornet Therapeutics
Active
BiotechUK· 2024
March Biosciences
March Biosciences
Active
BiotechUS· 2024
Ascend Advanced Therapies
Ascend Advanced Therapies
Active
BiotechUK· 2023

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns Cloverleaf Bio?

Cloverleaf Bio is currently owned by 4Bio Partners, through 4BIO Ventures III, since 2026.

When did 4Bio Partners acquire Cloverleaf Bio?

4Bio Partners acquired Cloverleaf Bio in 2026.

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue